Cutaquig(®) Is Well Tolerated in Immunodeficient Patients Who Did Not Tolerate Other Subcutaneous Immunoglobulin Products

Objective: Subcutaneous immunoglobulin (SCIG) treatment is generally tolerable, but some patients may experience adverse events to one or more SCIG products. We investigated whether 16.5% Cutaquig(®) treatment offered a tolerable and safe alternative treatment for immunodeficient patients. Methods:...

Descripción completa

Detalles Bibliográficos
Autores principales: Brownlee, Sydney, Allen, Crystal, Kana’an, Mohammed F., Cameron, D. William, Cowan, Juthaporn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680362/
https://www.ncbi.nlm.nih.gov/pubmed/36412628
http://dx.doi.org/10.3390/hematolrep14040048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680362/
https://www.ncbi.nlm.nih.gov/pubmed/36412628
http://dx.doi.org/10.3390/hematolrep14040048

Ejemplares similares